Method for treating a neurodegenerative disease by administering an anti-cellular prion protein (PrPc) antibody
US-12110336-B2 · Oct 8, 2024 · US
against prion molecules, e.g. CD230
against prion molecules, e.g. CD230 · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K16/2872 |
| Official title | {against prion molecules, e.g. CD230} |
| Display label | against prion molecules, e.g. CD230 |
| Total patents | 30 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
US-12098173-B2 · Sep 24, 2024 · US
Anti-doppel antibody drug conjugates
US-2024091372-A1 · Mar 21, 2024 · US
Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
US-2023220401-A1 · Jul 13, 2023 · US
Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
US-11549113-B2 · Jan 10, 2023 · US
Compositions and methods for the treatment and prevention of prion disease
US-2022313802-A1 · Oct 6, 2022 · US
Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
US-2022064233-A1 · Mar 3, 2022 · US
ANTI-PrP ANTIBODIES AND USES THEREOF
US-2021070870-A1 · Mar 11, 2021 · US
Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
US-2021032634-A1 · Feb 4, 2021 · US
Anti-PrP antibodies and uses thereof
US-10808034-B2 · Oct 20, 2020 · US
Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
US-10662246-B2 · May 26, 2020 · US
Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
US-10501549-B2 · Dec 10, 2019 · US
Methods and systems for predicting misfolded protein epitopes
US-10475525-B2 · Nov 12, 2019 · US
ANTI-PrP ANTIBODIES AND USES THEREOF
US-2019062442-A1 · Feb 28, 2019 · US
Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
US-10202459-B2 · Feb 12, 2019 · US
Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
US-2019010238-A1 · Jan 10, 2019 · US
Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
US-2019010504-A1 · Jan 10, 2019 · US
FasR antibodies and methods of use
US-10053510-B2 · Aug 21, 2018 · US
Cell senescence markers as diagnostic and therapeutic targets
US-2017298138-A1 · Oct 19, 2017 · US
Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
US-2017260278-A1 · Sep 14, 2017 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K16/2872?
- CPC C07K16/2872 is the Cooperative Patent Classification code for “against prion molecules, e.g. CD230.”
- How many patents are filed under CPC C07K16/2872 (against prion molecules, e.g. CD230)?
- Our database includes 30 publications tagged with this CPC code.
- Is patent activity under CPC C07K16/2872 growing?
- Publication counts under this code: 2 in 2023 vs 3 in 2024 (latest complete years).